We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Intuitive Surgical, HCA Healthcare, Exelon, 3M and Micron
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 14, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intuitive Surgical (ISRG - Free Report) , HCA Healthcare (HCA - Free Report) , Exelon (EXC - Free Report) , 3M (MMM - Free Report) and Micron (MU - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Intuitive Surgical, HCA Healthcare & Exelon
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intuitive Surgical, HCA Healthcare and Exelon. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Intuitive Surgical’s shares have outperformed the Zacks Medical Instruments industry in the past year, gaining +43.1% vs +14%. The Zacks analyst thinks strong prospects of the company’s robotic platform – da Vinci System – is a major positive.
Notably, da Vinci procedures recorded solid growth in recent times. This is led by growth in U.S. general surgery procedures and global urologic procedures. Regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system.
Management is also optimistic about the company’s collaboration with InTouch Health. On the negative side, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in the global MedTech space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.
Shares of Buy-ranked HCA Healthcare have outperformed the Zacks Hospital industry in the past year, gaining +56.6% vs +35.4%. The Zacks analyst thinks its top line has been growing over the last several quarters on higher admissions as well as improved payor and service mix.
A number of acquisitions helped the company gain a strong foothold in the industry, fueling its inorganic growth. The company has also raised its guidance from its previous projections. A strong balance sheet and free cash flow are a couple of other positives for the company.
However, its high operating expenses continue to weigh on the margins. The company is expected to witness a rise in costs due its constant growth-related investments, which in turn would not allow debts to go down, remaining a concern.
Buy-ranked Exelon’s shares have gained +14.9% in the past year, outperforming the Zacks Electric Power Industry which has gained +0.4% over the same period. The Zacks analyst thinks Exelon is going to benefit from its $21 billion planned capital investment, focus on zero emission electricity generation and cost savings.
The company continues with its hedging program to manage market risks and protect the value of its generation. Strong cash flow generation capacity will help it lower debt levels and increase value of its shareholders. However, Exelon is subject to the impact of commodity price volatility and price fluctuation in the wholesale markets. Stringent government regulation is also a cause of concern.
Other noteworthy reports we are featuring today include 3M and Micron.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Intuitive Surgical, HCA Healthcare, Exelon, 3M and Micron
For Immediate Release
Chicago, IL – December 14, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intuitive Surgical (ISRG - Free Report) , HCA Healthcare (HCA - Free Report) , Exelon (EXC - Free Report) , 3M (MMM - Free Report) and Micron (MU - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Intuitive Surgical, HCA Healthcare & Exelon
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intuitive Surgical, HCA Healthcare and Exelon. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Intuitive Surgical’s shares have outperformed the Zacks Medical Instruments industry in the past year, gaining +43.1% vs +14%. The Zacks analyst thinks strong prospects of the company’s robotic platform – da Vinci System – is a major positive.
Notably, da Vinci procedures recorded solid growth in recent times. This is led by growth in U.S. general surgery procedures and global urologic procedures. Regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system.
Management is also optimistic about the company’s collaboration with InTouch Health. On the negative side, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in the global MedTech space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company.
Shares of Buy-ranked HCA Healthcare have outperformed the Zacks Hospital industry in the past year, gaining +56.6% vs +35.4%. The Zacks analyst thinks its top line has been growing over the last several quarters on higher admissions as well as improved payor and service mix.
A number of acquisitions helped the company gain a strong foothold in the industry, fueling its inorganic growth. The company has also raised its guidance from its previous projections. A strong balance sheet and free cash flow are a couple of other positives for the company.
However, its high operating expenses continue to weigh on the margins. The company is expected to witness a rise in costs due its constant growth-related investments, which in turn would not allow debts to go down, remaining a concern.
Buy-ranked Exelon’s shares have gained +14.9% in the past year, outperforming the Zacks Electric Power Industry which has gained +0.4% over the same period. The Zacks analyst thinks Exelon is going to benefit from its $21 billion planned capital investment, focus on zero emission electricity generation and cost savings.
The company continues with its hedging program to manage market risks and protect the value of its generation. Strong cash flow generation capacity will help it lower debt levels and increase value of its shareholders. However, Exelon is subject to the impact of commodity price volatility and price fluctuation in the wholesale markets. Stringent government regulation is also a cause of concern.
Other noteworthy reports we are featuring today include 3M and Micron.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.